Table 2. Facility Characteristics and Patient Logistical Considerations in Pre–FDA Approval and Early Post–FDA Approval Eras.
| Characteristic | Facilities, No./total No. (%) | |||||
|---|---|---|---|---|---|---|
| NSCLCa | RCCb | Melanomac | ||||
| Pre–FDA approval | Early post–FDA approval | Pre–FDA approval | Early post–FDA approval | Pre–FDA approval | Early post–FDA approval | |
| Total facilities (any treatment), No.d | 1259 | 1294 | 1255 | 1261 | 1031 | 1063 |
| Facilities treating with immunotherapye | 934/1259 (74.2) | 1243/1294 (96.1) | 441/1255 (35.1) | 927/1261 (73.5) | 253/1031 (24.5) | 440/1063 (41.4) |
| Facility type | ||||||
| Community | 153/934 (16.4) | 263/1243 (21.1) | 37/441 (8.4) | 138/927 (14.9) | 17/253 (6.7) | 35/440 (8.0) |
| Comprehensive community program | 373/934 (39.9) | 476/1243 (38.3) | 179/441 (40.6) | 382/927 (41.2) | 87/253 (34.4) | 176/440 (40.0) |
| Academic | 174/934 (18.6) | 207/1243 (16.7) | 126/441 (28.6) | 192/927 (20.7) | 71/253 (28.1) | 113/440 (25.7) |
| Integrated network cancer program | 232/934 (24.8) | 296/1243 (23.8) | 93/441 (21.1) | 208/927 (22.4) | 52/253 (20.6) | 102/440 (23.2) |
| Unknownf | 68/934 (7.3) | 131/1243 (10.5) | 36/441 (8.2) | 77/927 (8.3) | 59/253 (23.3) | 67/440 (15.2) |
| Facility location | ||||||
| Northeast | 178/934 (19.1) | 243/1243 (19.5) | 85/441 (19.3) | 172/927 (18.6) | 43/253 (17.0) | 75/440 (17.0) |
| Midwest | 271/934 (29.0) | 347/1243 (27.9) | 119/441 (27.0) | 257/927 (27.7) | 66/253 (26.1) | 125/440 (28.4) |
| South | 336/934 (36.0) | 431/1243 (34.7) | 155/441 (35.1) | 324/927 (35.0) | 79/253 (31.2) | 143/440 (32.5) |
| West | 147/934 (15.7) | 221/1243 (17.8) | 76/441 (17.2) | 167/927 (18.0) | 39/253 (15.4) | 83/440 (18.9) |
| Unknownf | 68/934 (7.2) | 131/1243 (10.5) | 36/441 (8.2) | 77/927 (8.3) | 59/253 (23.3) | 67/440 (15.2) |
| Patients who received immunotherapy during era, No. | 6271 | 23 908 | 1155 | 3890 | 504 | 1143 |
| Residential classification of patient receiving immunotherapyg | ||||||
| Metropolitan | 5010/6271 (80.0) | 19 523/23 908 (81.7) | 931/1155 (80.6) | 3119/3890 (80.2) | 427/504 (84.7) | 923/1143 (80.8) |
| Urban | 933/6271 (14.9) | 3336/23 908 (14.0) | 152/1155 (13.2) | 573/3890 (14.7) | 58/504 (11.5) | 153/1143 (13.4) |
| Rural | 149/6271 (2.4) | 411/23 908 (1.7) | 31/1155 (2.7) | 83/3890 (2.1) | 7/504 (1.4) | 14/1143 (1.2) |
| Missing | 179/6271 (2.9) | 638/23 908 (2.7) | 41/1155 (3.5) | 115/3890 (3.0) | 12/504 (2.4) | 53/1143 (4.6) |
| Travel distance for patient receiving immunotherapy, milesg | ||||||
| 0-20 | 4109/6271 (65.5) | 14 733/23 908 (61.6) | 580/1155 (50.2) | 2016/3890 (51.8) | 246/504 (48.8) | 605/1143 (52.9) |
| >20-40 | 994/6271 (15.9) | 3311/23 908 (13.8) | 173/1155 (15.0) | 601/3890 (15.4) | 96/504 (19.0) | 185/1143 (16.2) |
| >40-60 | 356/6271 (5.7) | 1239/23 908 (5.2) | 84/1155 (7.3) | 258/3890 (6.6) | 42/504 (8.3) | 86/1143 (7.5) |
| >60 | 511/6271 (8.1) | 1597/23 908 (6.7) | 188/1155 (16.3) | 450/3890 (11.6) | 105/504 (20.8) | 200/1143 (17.5) |
| Missing | 301/6271 (4.8) | 3028/23 908 (12.7) | 130/1155 (11.3) | 565/3890 (14.5) | 15/504 (3.0) | 67/1143 (5.9) |
Abbreviations: FDA, Food and Drug Administration; NSCLC, non–small cell lung cancer; RCC, renal cell carcinoma.
For NSCLC, the pre–FDA approval era was 2011 to 2014, and the early post–FDA approval era was 2015 to 2017.
For RCC, the pre–FDA approval era was 2012 to 2015, and the early post–FDA approval era was 2016 to 2018.
For melanoma, the pre–FDA approval era was 2007 to 2010, and the early post–FDA approval era was 2011 to 2013.
Includes facilities that treated at least 1 patient with specified stage IV cancers with any treatment during the pre–FDA approval era.
Includes facilities that treated at least 1 patient with specified stage IV cancers with immunotherapy during the pre–FDA approval era. These data include the number and percentage of total facilities providing any treatment in the respective era.
Includes facilities that treated at least 1 patient aged 0 to 39 years. Facility type and location were suppressed for patients aged 0 to 39 years because of small sample sizes. Therefore, some hospitals were counted twice, and the total does not equal the total number of facilities providing treatment with immunotherapy.
Includes the number and percentage of patients who received immunotherapy in the respective era.